CAR T cell product | Axicabtagene ciloleucel (Yescarta) | Tisagenlecleucel (Kymriah) | Lisocabtagene maraleucel |
---|---|---|---|
Costimulation domain | CD-28 | 4-1BB | 4-1BB |
Vector | Retrovirus | Lentivirus | Lentivirus |
Conditioning regimen | Fludarabine, cyclophosphamide | Fludarabine, cyclophosphamide, or bendamustine | Fludarabine, cyclophosphamide |
Pivotal trial | ZUMA-1 (N = 108) | JULIET (N = 111) | TRANSCEND-NHL-001 (N = 102) |
Histology | DLBCL, tFL, PMBCL | DLBCL, tFL | DLBCL,PMBCL, FL, tFL |
CAR T cell dosage | 2 × 106 cells/kg | 3 × 108 cells/kg | 1 × 108 cells/kg |
ORR | 83% | 52% | 75% |
CR | 58% | 40% | 55% |
Median DOR (months) | 11.1 (95% CI, 4.2—NE) | NR (95% CI, 10—NR) | NA |
Overall survival | 24-month survival, 50.5% (95% CI 40.2–59.7) | 11.7 months (95% CI, 6.6—NE) | NA |
Any grade CRS/NT | 93%/64 % | 58%/21% | 37%/25 % |
Grade ≥ 3 CRS | 13% | 22% | 1% |
Grade ≥ 3 NT | 28% | 12% | 15% |
Tocilizumab/steroid usage | 43%/27% | 15%/10% | 17%/21% |
Grade 5 AEs | 4% | None | None |
Reference |